AbbVie (NYSE:ABBV) Cut to Hold at DZ Bank

DZ Bank lowered shares of AbbVie (NYSE:ABBV) from a buy rating to a hold rating in a report released on Tuesday morning, MarketBeat Ratings reports. They currently have $237.00 target price on the stock.

ABBV has been the subject of several other reports. Morgan Stanley boosted their price objective on AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price target on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Guggenheim increased their price objective on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Finally, Citigroup reduced their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $238.05.

AbbVie Trading Up 1.1%

ABBV opened at $219.13 on Tuesday. The firm’s fifty day moving average is $223.06 and its two-hundred day moving average is $201.96. The firm has a market cap of $387.11 billion, a PE ratio of 104.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is 524.24%.

Insider Activity

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.25% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently bought and sold shares of the business. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie in the second quarter valued at about $26,000. TD Capital Management LLC lifted its stake in shares of AbbVie by 82.9% during the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the 2nd quarter worth about $28,000. Finally, Abound Financial LLC acquired a new position in AbbVie in the 1st quarter valued at about $30,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.